<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797847</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-TTRSC02-001</org_study_id>
    <nct_id>NCT02797847</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Single-Blind, Placebo Controlled, Single-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-TTRSC02 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, pharmacokinetics and
      pharmacodynamics of ALN-TTRSC02 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2016</start_date>
  <completion_date type="Actual">January 12, 2018</completion_date>
  <primary_completion_date type="Actual">January 12, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of ALN-TTRSC02, evaluated by the proportion of subjects experiencing adverse events (AEs)</measure>
    <time_frame>Day 1 through to Day 314</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-TTRSC02</measure>
    <time_frame>Day 1 through to Day 3</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-TTRSC02</measure>
    <time_frame>Day 1 through to Day 3</time_frame>
    <description>tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-TTRSC02</measure>
    <time_frame>Day 1 through to Day 3</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-TTRSC02</measure>
    <time_frame>Day 1 through to Day 3</time_frame>
    <description>t½</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-TTRSC02</measure>
    <time_frame>Day 1 through to Day 3</time_frame>
    <description>CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-TTRSC02</measure>
    <time_frame>Day 1 through to Day 3</time_frame>
    <description>Vss/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-TTRSC02</measure>
    <time_frame>Day 1 through to Day 3</time_frame>
    <description>Vz/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-TTRSC02</measure>
    <time_frame>Day 1 through to Day 314</time_frame>
    <description>fe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics (PK) of ALN-TTRSC02</measure>
    <time_frame>Day 1 through to Day 314</time_frame>
    <description>CLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ALN-TTRSC02 on serum TTR levels as measured by reduction from baseline in serum TTR</measure>
    <time_frame>Day 1 through to Day 314</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ALN-TTRSC02 on serum Vitamin A levels as measured by reduction from baseline in serum Vitamin A</measure>
    <time_frame>Screening through to Day 314</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)</condition>
  <arm_group>
    <arm_group_label>ALN-TTRSC02</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile normal saline 0.9% for SC administration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALN-TTRSC02</intervention_name>
    <description>Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection</description>
    <arm_group_label>ALN-TTRSC02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Calculated volume to match active comparator</description>
    <arm_group_label>Sterile normal saline 0.9% for SC administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects, age 18 to 65 years, inclusive.

          -  Body mass index (BMI) ≥18.0 kg/m2 and ≤30 kg/m2 assessed at Screening.

          -  No clinically significant health concerns, as determined by medical history and
             physical examination, in the opinion of the Investigator.

          -  Women of child bearing potential must have a negative pregnancy test, cannot be
             breastfeeding, and must be willing to use contraception, willing and able to comply
             with the study requirements and to provide written informed consent.

          -  For Japanese cohorts, subjects of Japanese descent are defined as people carrying a
             Japanese passport, descendants of 4 Japanese grandparents, and have not been outside
             Japan for more than 5 years.

        Exclusion Criteria:

          -  Clinically relevant history or presence of respiratory, gastrointestinal, renal,
             cardiovascular, hepatic, hematological, lymphatic, neurological, psychiatric,
             musculoskeletal, genitourinary, immunological, and other inflammatory diseases, or
             dermatological or connective tissue diseases or disorders.

          -  Active serious mental illness or psychiatric disorder.

          -  Clinically significant ECG abnormalities. Abnormal for AST/ALT and any other clinical
             safety laboratory result considered clinically significant.

          -  Known history of allergic reaction to an oligonucleotide or GalNAc.

          -  History of intolerance to subcutaneous injection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Vest, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TTR-mediated Amyloidosis</keyword>
  <keyword>Amyloidosis, Hereditary</keyword>
  <keyword>Amyloid Neuropathies, Familial</keyword>
  <keyword>Familial Amyloid Polyneuropathies</keyword>
  <keyword>Amyloid Neuropathies</keyword>
  <keyword>Amyloidosis, Hereditary, Transthyretin-Related</keyword>
  <keyword>Familial Amyloidosis</keyword>
  <keyword>RNAi therapeutic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

